Neutrophil extracellular traps (NETs) contribute to immunothrombosis and have been associated with mortality in coronavirus disease 2019 (COVID-19). We stimulated donor neutrophils with plasma from patients with COVID-19 and demonstrated that R406 can abrogate the release of NETs. These data provide evidence for how fostamatinib may mitigate neutrophil-associated mechanisms contributing to COVID-19 immunopathogenesis.
Trial registration: ClinicalTrials.gov NCT04579393.
Keywords: COVID-19; fostamatinib; immunothrombosis; neutrophil extracellular traps.
Published by Oxford University Press for the Infectious Diseases Society of America 2020.